Indexed In
- Open J Gate
- Academic Keys
- RefSeek
- Hamdard University
- EBSCO A-Z
- Publons
- Geneva Foundation for Medical Education and Research
- Google Scholar
Useful Links
Share This Page
Journal Flyer
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
Corneal toxicity related with multiple myeloma treatment
Joint Event on 39th European Ophthalmology Congress 11th World Congress on Health Economics, Health Policy and Healthcare Management
March 18, 2025 Webinar
Tamara Shukair
Hospital Universitario Madrid Norte Sanchinarro, Spain.
Posters & Accepted Abstracts: Health Care Curr Re
Abstract:
Background and Purpose: Multiple myeloma (MM) is an incurable haematological cancer Among the treatments, an antibody-drug conjugate (ADC, also known as immunoconjugate) targeting the B cell maturation antigen (BCMA) is used, with known corneal toxicity, which should be monitored during treatment cycles. Methods: We present 5 patients treated with monoclonal antibody for multiple myeloma, with no prior ocular history. The patients presented ocular symptoms one week after receiving the treatment with very significant visual acuity impairment where they were diagnosed with bilateral corneal toxicity in the form of microcysts and sub epithelial deposits, in addition to grade III keratitis. Results: They were treated with topical corticosteroids, artificial tears, and therapeutic contact lenses. Also, it was necessary to stop the oncological treatment (for a time) and then modify its dose in order to control the ocular side effects. Conclusions: Monoclonal antibodies can have significant corneal toxicity, and it is directly related to the dose. Ophthalmologists have to identify and manage the side effects of new medications.
Biography :
Dr. Tamara Shukair,holds a Ph.D. in Ophthalmology and serves as the Medical Executive of the Uveitis Unit at North Madrid Hospital Sanchinarro. She is also an Ophthalmology Consultant for the Ocular Toxicity of Cancer New Therapy at START Madrid Group at Clara Cambal Hospital (CIOCC). Additionally, she is responsible for Preventive Ophthalmology and the evaluation of ocular work-related injuries at the Central Hospital of Fraternidad and Telefonica Medical Centre in Madrid. Dr. Tamara Shukair is an active member of the Spanish Society of Ophthalmology